Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1

Status

Active not recruiting 12Recruiting 9Completed 7Unknown 3Not yet recruiting 3Terminated 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Breast 1

Conditions

Prostatic Neoplasms 3Carcinoma, Intraductal, Noninfiltrating 1

Interventions

Carboplatin 75Cisplatin 73Bevacizumab 64Radiotherapy 57Drug Therapy 56Capecitabine 56tislelizumab 54Oxaliplatin 54Gemcitabine 46toripalimab 45Paclitaxel 45Specimen Handling 43sintilimab 39pembrolizumab 39anlotinib 38Cyclophosphamide 33130-nm albumin-bound paclitaxel 32Magnetic Resonance Spectroscopy 27Injections 27camrelizumab 26Pemetrexed 26Surgical Procedures, Operative 25lenvatinib 23Docetaxel 23Biopsy 23apatinib 22Etoposide 22Immune Checkpoint Inhibitors 21S 1 (combination) 20Fluorouracil 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × darolutamide × Clear all
NCT07476677 2026-03-17

ANDARP

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
60 enrolled
Genitourinary

Prostatic Neoplasms

NCT07282197 2025-12-15

Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019

Peking University First Hospital

Phase 2 Not yet recruiting
40 enrolled
Genitourinary

Prostatic Neoplasms

NCT04176081 2024-01-24

SChLAP/IDC

University Health Network, Toronto

Phase 2 Not yet recruiting
208 enrolled
BreastGenitourinary

Carcinoma, Intraductal, Noninfiltrating, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡